IL17A and psoriasis: In an imiquimod (IMQ)-induced psoriasis mouse model, treatment with CA-EVs@GHM suppressed pro-inflammatory cytokines (TNF, IL-6, IL-17A, IL-22, IL-23A), restored skin barrier function and microbial diversity, reduced S. aureus colonization, and inhibited ILC2-to-ILC3 conversion—ultimately reducing IL-17 and IL-22 secretion [98].